Enhanced osteogenic differentiation in Zoledronate-treated osteoporotic patients by Dalle Carbonare, Luca et al.
 International Journal of 
Molecular Sciences
Article
Enhanced Osteogenic Differentiation in
Zoledronate-Treated Osteoporotic Patients
Luca Dalle Carbonare 1, Monica Mottes 2, Giovanni Malerba 2, Antonio Mori 1,2,
Martina Zaninotto 3, Mario Plebani 3, Alessandra Dellantonio 1 and Maria Teresa Valenti 1,*
1 Department of Medicine, Internal Medicine, Section D, University of Verona, Piazzale Scuro,
10, 37134 Verona, Italy; luca.dallecarbonare@univr.it (L.D.C.); antonio.mori@univr.it (A.M.);
alessandra.dellantonio@univr.it (A.D.)
2 Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale Scuro,
10, 37134 Verona, Italy; monica.mottes@univr.it (M.M.); giovanni.malerba@univr.it (G.M.)
3 Department of Laboratory Medicine Azienda Ospedaliera, University of Padova Via Giustiniani,
2, 35128 Padova, Italy; martina.zaninotto@unipd.it (M.Z.); mario.plebani@unipd.it (M.P.)
* Correspondence: mariateresa.valenti@univr.it; Tel.: +39-045-812-8450; Fax: +39-045-802-7496
Academic Editor: Nicholas Delihas
Received: 17 May 2017; Accepted: 7 June 2017; Published: 13 June 2017
Abstract: Bisphosphonates are well known inhibitors of osteoclast activity and thus may be
employed to influence osteoblast activity. The present study was designed to evaluate the in vivo
effects of zoledronic acid (ZA) on the proliferation and osteoblastic commitment of mesenchymal
stem cells (MSC) in osteoporotic patients. We studied 22 postmenopausal osteoporotic patients.
Densitometric, biochemical, cellular and molecular data were collected before as well as after 6 and
12 months of ZA treatment. Peripheral blood MSC-like cells were quantified by colony-forming
unit fibroblastic assay; their osteogenic differentiation potential was evaluated after 3 and
7 days of induction, respectively. Circulating MSCs showed significantly increased expression
levels of osteoblastic marker genes such as Runt-related transcription factor 2 (RUNX2), and
Osteonectin (SPARC) during the 12 months of monitoring time. Lumbar bone mineral density
(BMD) variation and SPARC gene expression correlated positively. Bone turnover marker levels were
significantly lowered after ZA treatment; the effect was more pronounced for C terminal telopeptide
(CTX) than for Procollagen Type 1 N-Terminal Propeptide (P1NP) and bone alkaline phosphatase
(bALP). Our findings suggest a discrete anabolic activity supported by osteogenic commitment of
MSCs, consequent to ZA treatment. We confirm its anabolic effects in vivo on osteogenic precursors.
Keywords: mesenchymal stem cells; Runt-related transcription factor 2 (RUNX2); zoledronic acid;
gene expression; bone turnover; differentiation
1. Introduction
Osteoporosis is a degenerative disease associated with bone fractures affecting mobility and
increasing mortality and morbidity in older populations [1]. Bone resorption is associated with
osteoclastic activity, and increases in postmenopausal osteoporosis leading to an imbalance in bone
homeostasis. However, the bone loss observed with aging is not only associated with the increased
activity of osteoclasts, but also with a progressive decline in osteoblast number, function, and survival
that is concurrent to the generation of bone formation impairment [2]. The ability to produce an
adequate number of functional osteoblasts is pivotal for bone mass preservation. With regard to
this aspect, it has been demonstrated that bone remodeling involves the proliferation and osteogenic
differentiation of mesenchymal stem cells [3]. Mesenchymal stem cells (MSC) can also differentiate
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into adipocytes; a mutually inhibitory relationship exists between osteogenic and adipogenic lineage
commitment [4].
According to this observation, histomorphometric analyses revealed adipocytic replacement in
the bone marrow of postmenopausal osteoporotic patients [5]; furthermore, we have demonstrated
in a previous study that mesenchymal stem cells of osteoporotic patients have an abnormal
osteogenic differentiation [6]. Recently, we also demonstrated that the osteogenic master factor
Runt-related transcription factor 2 (RUNX2) downregulation and the adipogenic master gene
Peroxisome Proliferator Activated Receptor Gamma PPARG2 upregulation in osteoporotic patients
may be enhanced by modified lipoproteins derived from the oxidation of arachidonate-containing
phospholipids (ox-PAPCs) [7]. This imbalance between osteoblastogenesis and adipogenesis has
been considered in order to develop therapies capable of promoting osteoblastogenesis or inhibiting
adipogenesis [8], although current treatments for osteoporosis are still mainly represented by
drugs with antiresorptive effects such as bisphosphonates (BPs). Bisphosphonates are analogues of
pyrophosphate with a high affinity to hydroxyapatite crystals that increases their efficacy in metabolic
bone diseases. They maintain bone strength further than what is expected on the basis of the moderate
bone mineral density increase that they induce.
Even if BPs are considered antiresorptive drugs, this mode of action cannot fully account for
their efficacy on fracture reduction. Many studies suggest that they can also promote osteogenesis
through different mechanisms involving mesenchymal stromal cell differentiation [9–11] and/or
reduction of bone marrow fat [12]. In this regard, it has been observed that in vitro short-term exposure
to zoledronic acid (ZA) enhanced osteogenic differentiation and mineralization of mesenchymal
stem cells, suggesting a direct positive effect of BPs on osteogenic precursors [13]. There is now
a growing body of evidence suggesting that the preventive effects of BPs on bone loss may also
be ascribed to their anabolic activity on cells of the osteogenic lineage. BPs control osteoblastic
functions such as proliferation and differentiation [14], prevent osteoblast apoptosis [15], modulate
osteoblastic production of extracellular matrix proteins [16,17], and also regulate osteoblastic expression
and secretion of various growth factors and cytokines [18,19]. Thus, it has been hypothesized that
osteoblasts are the complementary elements required for the complete antiresorptive effects of these
drugs [20].
Since the dynamic equilibrium of bone turnover is maintained by the commitment of MSCs as well
as by osteoclastic activity, it is interesting to analyze the modulation of both cell types after exposure to
BP treatment. Many studies on the effects of BPs on osteoclasts have been reported [21]. Despite the
combination of bone resorption and bone formation, the effects of BPs on MSCs have not been
investigated in treated osteoporotic patients so far. Effectively, while in vitro studies have suggested a
direct effect of BPs on osteogenesis, few studies have been performed by stimulating in vitro MSCs
harvested from patients [22]. Thus, the in vivo modulation of MSCs in BP-treated patients has not yet
been explained. Data obtained from weekly ZA-treated rats demonstrated that treatment stimulates
the ex vivo proliferation of their MSCs, but has no effect on osteoblastic differentiation [23].
In this study, we describe for the first time the ex vivo effects on MSCs isolated from osteoporotic
patients after a single infusion of ZA in terms of proliferation and osteogenic gene expression. We also
provide data showing the relationship between molecular osteogenic levels, bone mineral density, and
bone turnover markers.
2. Results
The experimental design is represented in Figure 1. The main characteristics of the study
population at the baseline and 12 months after treatment are reported in Table 1.
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Figure 1. Schematic representation of the experimental design. 
Table 1. Anthropometric, densitometric, and biochemical data of the study population. 
Parameter 
Baseline Values 
(Mean ± SD) 
12 Months Values  
(Mean ± SD) p Value 
Age (years) 62 ± 11   
Weight (kg) 63 ± 10 - - 
height (m) 1.54 ± 0.06 - - 
BMI (kg/m2) 26 ± 5   
Lumbar BMD (g/cm2) 0.710 ± 0.128 0.76 ± 0.11 0.045 
LumbarT-score (SD) −2.9 ± 1.0 −2.5 ± 0.97 0.001 
Lumbar Z-score (SD) −1.4 ± 1.2 −0.98 ± 1.25 0.001 
Femoral neck BMD (g/cm2) 0.608 ± 0.08 0.6 ± 0.07 0.78 
Femoral neck T-score (SD) −2.2 ± 0.74 −2.2 ± 0.64 0.71 
Femoral neck Z-score (SD) −0.8 ± 0.8 0.74 ± 0.71 0.204 
Total hip BMD (g/cm2) 0.728 ± 0.086 0.73 ± 0.08 0.15 
Total hip T-score (SD) −1.8 ± 0.71 −1.7 ± 0.71 0.006 
Total hip Z-score (SD) −0.7 ± 0.8 −0.57 ± 0.83 0.002 
Creatinine (mg/dL) 0.73 ± 0.15 0.73 ± 0.17 0.255 
s-Calcium (mg/dL) 9.2 ± 0.2 9.4 ± 0.3 0.014 
Calcium/creatinine (mg/mg) 0.140 ± 0.095 0.09 ± 0.06 0.023 
ALP (U/L) 79.8 ± 21.7 72.06 ± 30.1 0.026 
CTX (ng/mL) 0.525 ± 0.206 0.21 ± 0.1 0.001 
PTH (pg/mL) 59.2 ± 32.8 80 ± 32 0.002 
25-OH vitamin D (ng/mL) 31.5 ± 20.5 33.23 ± 12.37 0.07 
BMI, body mass index; BMD, bone mineral density; ALP, alkaline phosphatase; CTX, C terminal 
telopeptide; PTH, parathormon; 25-OH, 25-hydroxy-vitamin D. 
2.1. Densitometric and Biochemical Evaluation 
All patients showed bone densitometric values lower than −2.5 SD at the lumbar spine or other 
skeletal sites, according to the inclusion criteria. 
At the baseline, five patients out of 22 showed 25-hydroxy (25-OH)–vitamin D levels below the 
normal values, while all patients presented normal values of parathormon (PTH), C terminal 
telopeptide (CTX), and other metabolic parameters. After cholecalciferol supplementation, all 
patients were in the normal vitamin D range; vitamin D levels did not change during the study. In 
the study group, after ZA treatment, we observed a significant reduction of serum calcium and 
calcium excretion levels with a secondary significant increase of PTH. 
  
Figure 1. Schematic representation of the experimental design.
Table 1. Anthropometric, densitometric, and biochemical data of the study population.
Parameter Baseline Values(Mean± SD)
12 Months Values
(Mean± SD) p Value
Age (years) 62 ± 11
Weight (kg) 63 ± 10 - -
height (m) 1.54 ± 0. 6 - -
BMI (kg/ 2 26 5
Lumbar BMD (g/cm2) 0.710 ± 0.128 0.76 ± 0.11 0.045
LumbarT-score (SD) −2.9 ± 1.0 −2.5 ± 0.97 0.001
Lumbar Z-score (SD) −1.4 ± 1.2 −0.98 ± 1.25 0.001
Femoral neck BMD (g/cm2) 0.608 ± 0.08 0.6 ± 0.07 0.78
Femoral neck T-score (SD) −2.2 ± 0.74 2.2 ± 0.64 .71
Femor l Z-score (SD) −0.8 .8 0.74 0.71 0.204
Total hip BMD (g/cm2) 0.728 ± 0.086 0.73 ± 0.08 0.15
Total hip T-score (SD) −1.8 ± 0.71 −1.7 ± 0.71 0.006
Total hip Z-score (SD) −0.7 ± 0.8 −0.57 ± 0.83 0.002
Creatinine (mg/dL) 0.73 ± 0.15 0.73 ± 0.17 0.255
s-Calc um (mg/dL) 9.2 ± .2 9.4 ± .3 0.014
Calcium/creatinine (mg/mg) 0.140 ± 0.095 0.09 ± 0.06 0.023
ALP (U/L) 79.8 ± 21.7 72.06 ± 30.1 0.026
CTX (ng/mL) 0.525 ± 0.206 0.21 ± 0.1 0.001
PTH (pg/mL) 59.2 ± 32.8 80 ± 32 0.002
25-OH vitamin D (ng/mL) 3 .5 ± 20.5 33.23 ± 12.37 . 7
BMI, body mass index; BMD, bone mineral density; ALP, alkaline phosphatase; CTX, C terminal telopeptide; PTH,
parathormon; 25-OH, 25-hydroxy-vitamin D.
2.1. Densitometric and Biochemical Evaluation
All patients showed bone densitometric values lower than −2.5 SD at the lumbar spine or other
skeletal sites, according to the inclusion criteria.
At the baseline, five patients out of 22 showed 25-hydroxy (25-OH)–vitamin D levels below
the normal values, while all patients presented normal values of parathormon (PTH), C terminal
telopeptide (CTX), and other metabolic parameters. After cholecalciferol suppl mentation, all patients
were in the normal v tamin D range; vitamin D levels did not change during the study. In the study
group, after ZA treatment, we observed a significant reduction of serum calcium a d calcium excretion
levels with a secondary significa t increase of PTH.
2.2. Bone Turnover Markers
We observed a significant incr ase of b ne miner l de sity (BMD) 12 months after ZA infusion.
Consistently, we observed a decrease in bone turnover markers (CTX, P1NP and ALP) evaluated
after 6 months of treatment; the decrease was more pronounced for CTX than for P1NP and bALP.
Both turnover marker values rose between 6 and 12 months, although they remained lower than
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those at baseline. Interestingly, SPARC and COL1A1 gene expression showed the same trend of bone
formation markers (P1NP and ALP) between 6 and 12 months (Figure 2).
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Figure 2. Mean values of bone metabolism/osteogenic differentiation markers across the time points. 
Biochemical values were obtained from blood samples; qRT-PCR values obtained from differentiating 
cells were utilized as gene expression markers. For each marker, mean values were calculated from 
the standardized z-score. The lumbar BMD increase during treatment correlated significantly with 
the expression of osteogenic marker SPARC (p < 0.05); COL1A1 gene expression showed an analogous 
trend without reaching any statistical significance (p > 0.05). 
2.3. Colony Forming Unit-Fibroblastic (CFU-F) Evaluation 
The MSC-like obtained by the depletion method of mononuclear cells (MNCs) from the controls 
and patients expressed cluster differentiation markers at similar levels (Table 2). After 14 days of 
cultivation, we assayed CFU-F and a higher number was observed at baseline of treated patients (5.67 
Figure 2. Mean values of bone metabolism/osteogenic differentiation markers across the time points.
Biochemical values were obtained from blood samples; qRT-PCR values obtained from differentiating
cells were utilized as gene expression markers. For each marker, mean values were calculated from
the standardized z-score. The lumbar BMD increase during treatment correlated significantly with
the expression of osteogenic marker SPARC (p < 0.05); COL1A1 gene expression showed an analogous
trend without reaching any statistical significance (p > 0.05).
2.3. Colony Forming Unit-Fibroblastic (CFU-F) Evaluation
The MSC-like obtained by the depletion method of mononuclear cells (MNCs) from the controls
and patients expressed cluster differentiation markers at similar levels (Table 2). After 14 days of
cultivation, we assayed CFU-F and a higher number was observed at baseline of treated patients
(5.67 ± 1.7) compared to normal donors (2.52 ± 1.69). Therefore, we observed a decreased frequency
of CFU-F obtained after 6 (3 ± 1.6) (p < 0.05) and 12 months (2.77 ± 1.7) (p < 0.05) of ZA infusion to
osteoporotic patients (OP) compared to the pre-therapy condition (5.45 ± 2.8) (Figure 3A).
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Table 2. Cell phenotype of MSC-like after depletion.
Cluster Differentiation Controls Pre-Therapy 6 Months PT 12 Months PT
CD3 0% 0% 0% 0%
CD14 0.48 ± 0.06% 0.70% (±0.04) 0.60% (±0.60) 0.80% (±0.07)
CD19 0% 0% 0% 0%
CD45 2.30 ± 0.47% 1.89% (±0.30) 1.70% (±0.80) 1.90% (±0.50)
CD34 Low level Low level Low level Low level
PT, post-therapy.
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Figure 3. Peripheral blood derived-MSCs and osteogenic differentiation after ZA infusion. Cellular 
and molecular analyses display the reduction of Colony Forming Unit-Fibroblastic (CFU-F) (A) and 
the increase of osteogenic expression (B) during the treatment. The values are representative of 22 
patients at each observation time. Three independent qRT-PCRs were performed at the same time for 
each gene. The overall information suggests an enhanced osteoblastogenesis in ZA-treated patients. 
(* p < 0.05 vs. pre-therapy; # p < 0.05 vs. 6 months). 
2.4. Gene Expression 
In order to track the osteogenic gene expression, we evaluated the levels of RUNX2 after 3 days 
of differentiation, as this gene is a marker for early commitment of MSCs [24]. SP7, SPP1, SPARC, 
COL1A1, Osteocalcin, and ALP marker levels were instead evaluated after 7 days of culture in 
osteogenic medium, in order to analyze the progression of the phenotype in committed mesenchymal 
cells. As reported in Figure 3B, RUNX2 gene expression showed a nearly 10-fold increase after 6 
months of treatment; after 12 months, it settled to levels still significantly higher compared to the pre-
Figure 3. Peripheral blood derived-MSCs and osteogenic differentiation after ZA infusion. Cellular and
molecular analyses display the reduction of Colony Forming Unit-Fibroblastic (CFU-F) (A) and the
increase of osteogenic expression (B) during the treatment. The values are representative of 22 patients
at each observation time. Three independent qRT-PCRs were performed at the same time for each gene.
The overall information suggests an enhanced osteoblastogenesis in ZA-treated patients. (* p < 0.05 vs.
pre-therapy; # p < 0.05 vs. 6 months).
2.4. Gene Expression
In order to track the osteog nic gene expression, we evaluated the l v ls of RUNX2 after 3 days of
differentiatio , as this gene is a marker for early commitment of MSCs [24]. SP7, SPP1, SPARC COL1A1,
Osteocalcin, and ALP marker levels were instead valua d after 7 days of culture in osteogenic
medium, in ord r to analyze the progr ssion f the phenoty e in committed mesenchymal cells.
As reported in Figure 3B, RUNX2 gene expression showed a nearly 10-fold increase after 6 months of
treat ent; after 12 onths, it settled to levels still significantly higher compared to the pre-treatment
levels (p < 0.05). Also, the expression levels of SP7, SPP1, SPARC, COL1A1, Osteocalcin, and ALP
were higher after 6 and 12 months compared to the pre-treatment levels. In addition, we observed
a significantly increased expression of SPP1, SPARC, Osteocalcin, COL1A1, and ALP after 12 months
Int. J. Mol. Sci. 2017, 18, 1261 6 of 11
compared to 6 months of treatment (p < 0.05). As for the modulation of RANKL, we observed a lower
gene expression after 6 and 12 months of treatment. This reduction reached a statistical significance
after 6 months (p < 0.05).
The increase of BMD at the lumbar spine after ZA infusion correlated positively (r2 = 0.147) with
the expression of SPARC, a marker gene of mature osteoblast, evaluated in osteoporotic (OP) patients
MSC-like after 7 days of differentiation. (Figure 4). This gene was noted to be a predictor of lumbar
bone density by the covariance analysis (p < 0.05).
In order to evaluate a possible effect of ZA on the adipogenic lineage, we analyzed PPARG2 gene
expression in MSCs-like after 6 and 12 months of treatment. As reported in Figure 3B, no statistically
significant change was observed during treatment, compared to pre-therapy levels.
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3. Discussion
BPs are considered frontline agents against osteoporosis and are the most prescribed treatments
for the prevention of bone loss and related fractures [25,26]. It is known that BPs act mainly by
inhibiting osteoclast activity, but growing evidence indicates that they may stimulate osteoblast
differentiation as well. We have addressed this issue by monitoring the effects of a single ZA infusion
on 22 osteoporotic patients. Biochemical, densitometric, radiologic, and molecular data concerning
expression levels of osteogenic marker genes were recorded at baseline as well as 6 and 12 months after
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treatment. As expected, bone turnover markers levels were significantly lowered after ZA treatment
and we also observed a reduction of RANKL gene expression in MSCs-like after 6 months of treatment.
The effect was more pronounced for CTX than for P1NP and ALP. Likewise, a similar pattern was
observed in the second 6-month period following ZA infusion; the difference between levels of bone
resorption/bone formation markers was maintained during the study. This last finding suggests a
fairly appreciable anabolic activity supported by osteogenic commitment of MSC-like. Despite the
inherent limitations of an ex vivo MSC differentiation model, our data suggest that the observed
BMD increase in patients after treatment correlates with enhanced osteoblastogenesis, substantiated
by the significantly increased expression levels of osteoblastic marker SPARC. By comparing the
gene expression of peripheral blood derived (PB)-MSCs after 6 and 12 months of ZA infusion, we
observed an enhanced osteogenic commitment, and the gene expression levels were higher compared
to baseline (before ZA treatment). The most evident increase in expression levels of RUNX2, the early
osteogenic commitment marker, was monitored in PB-MSCs of patients 6 months after ZA infusion;
after 12 months, RUNX2 gene expression was still significantly higher than at baseline. A similar
trend was observed for its downstream transcription factor SP7. The expression of bone extracellular
matrix (ECM) markers, such as COL1A1, SPARC, Osteocalcin, and ALP, constantly increased during
the 12 months of monitoring time, suggesting enhanced bone formation. Lumbar BMD variation and
SPARC gene expression were positively correlated. In addition, in our study we did not observe any
effect of ZA on adipogenic differentiation, evaluated by PPARG2 gene expression levels in MSCs-like.
Levels of PB-MSC of osteoporotic patients, evaluated for their capacity to give rise to fibroblastic
colonies (CFU-F), were significantly higher before treatment than after 12 months of treatment. In our
experience, levels of circulating MSCs were consistently higher in untreated osteoporotic patients than
in normal donors [6]. This may reflect an enhanced mobilization of MSCs to produce osteogenic cells as
a consequence of increased bone turnover. Interestingly, values recorded after treatment (mean ± SD,
2.7 ± 1.68) reproduced those observed in PB-MSC of normal donors, suggesting a normalization of
bone turnover promoted by ZA.
Our investigation, focusing particularly on the ex vivo effects at the molecular and cellular level
of ZA treatment, supports its anabolic effects on osteogenic precursors, previously demonstrated
in vitro [27] and in a sickle cell disease mouse model [28].
The relationship between osteogenic gene expression and bone turnover markers supports the
hypothesis that the significant increase in bone density after ZA treatment is not only due to the
inhibition of bone turnover, but also due to new bone formation as a consequence of the commitment
of mesenchymal stem cells through the osteogenic lineage. The stimulation of osteoblasts, following
turnover inhibition, shows the potential anabolic activity of ZA, already described to explain the
anabolic action of teriparatide [29]. This mode of action might be peculiar to ZA, considering the
different bone turnover profiles generated by other BPs, e.g., risedronate, in a specific context [30].
The peculiar activity of ZA demonstrated in this study suggests its employment not only in
clinical conditions characterized by increased bone turnover, but also in other disorders, where
osteoblastic activity results are affected. This a perspective may explain the powerful effect of
ZA in glucocorticoid-induced osteoporosis, a condition characterized by a significant decrease of
osteogenic activity, associated with the depletion of osteoblastic precursors and apoptosis of mature
cells. The bivalent effect of ZA is of clinical relevance considering a possible modulation in its
administration schedule, singly or in association with other drugs, using a sequential approach.
4. Materials and Methods
4.1. Ethics Statement
Written informed consent was obtained from all participants and the study was approved by
the Ethical Committee of Azienda Ospedaliera Universitaria Integrata of Verona, Italy (number 1538;
3th December, 2012; Local Ethical Committee of Azienda Ospedaliera Integrata di Verona).
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4.2. Patients
We selected 22 postmenopausal OPs who had been consecutively referred to our Metabolic Bone
Disease Centre in a 6-month interval (from January to June) of 2012. We compared biochemical and
molecular data of these patients before and after 6 and 12 months of ZA treatment. None of the patients
or controls were taking any therapy before the enrolment. At baseline, before ZA infusion, patients were
supplemented with a bolus of 300.000 UI of cholecalciferol for two days, followed by a monthly dosage
of 100.000 UI per os. Exclusion criteria included premature menopause (younger than 45 years old), or
presence of a disease or use of a drug that could affect bone or calcium/phosphate metabolism.
At baseline and 12 months after ZA (5 mg, Novartis Basel, Switzerland) infusion, all women
included in the study underwent a densitometric (DXA) measurement at the lumbar spine and hip
(Hologic QDR Discovery Acclaim, Waltham, MA, USA) and osteoporosis was diagnosed according to
World Health Organization (WHO) parameters. A lumbar spine or femoral T score lower than 2.5 SD
was considered as the cut-off [31].
Biochemical evaluations were performed on all OPs in order to rule out secondary causes
of osteoporosis (S-calcium (Ca), S-phosphate (P), calcium/creatinine ratio (CaE), Parathyroid
Hormone (PTH), carboxy-terminal telopeptide of type I collagen (CTX), alkaline phosphatase (ALP),
25-hydroxyvitamin D (VitD)). In addition, cholesterol levels and CRP (C Reactive Protein) were
evaluated. Patients with low levels of vitamin D were supplemented and enrolled when normal levels
were reached.
4.3. Sample Collection for Serum and Circulant MSCs-Like
The serum was obtained from 10 mL of fresh blood by centrifugation at 400× g and frozen
at −80 ◦C until use. MSC-like cells were isolated from 50 mL of heparinised blood using two
Ficoll procedures to deplete hematopoietic cells by antibodies cocktail, as previously reported [32].
The enriched cells obtained were washed in phosphate buffered saline (PBS) and analyzed for
gene expression.
4.4. Analysis of Cell Phenotype
We analyzed gene expression for CD3, CD14, CD19, CD45, and CD34 markers, as previously
reported [32]. This method allowed phenotypic analysis in a small number of cells obtained by
stringent stem-cell purification strategies, as previously described [33].
4.5. Quantification of Human Mesenchymal Progenitors (CFU-F)
To evaluate the number of CFU-F assays, MSC-like were seeded at three different concentrations
(4× 105, 2× 105, 1× 105) in 24-well plates and incubated for 14 days in medium containing MesenCult
MSC Stimulatory Supplement (#05402, StemCell Technologies Inc., Vancouver, BC, Canada) under
a humidified atmosphere of 5% CO2 at 37 ◦C, as previously reported [32]. After 14 days, adherent
cells were fixed with methanol and stained for 5 min with Giemsa staining solution. After washing
with distilled water, colonies consisting of more than 50 cells were scored on an inverted microscope.
The CFU-Fs were expressed as an average of the three different culture concentrations.
4.6. Osteogenic Differentiation
The osteogenic differentiation was obtained by using osteogenic medium containing 15%
of Osteogenic Stimulatory Supplements (#05404, Stemcell), 10−8 M dexamethasone, 3.5 mM
β-glycerophosphate, and 50 µg/mL ascorbic acid (StemCell Technologies Inc., Vancouver, BC, Canada),
as previously reported [32]. The medium was changed every 3 days after initial plating. After 3, 7, and
14 days of osteogenic induction, cells were harvested and the pellet was processed or stored at −80 ◦C
until use.
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4.7. Total RNA Extraction
Total RNA was extracted by using the RNAeasy minikit (Quiagen, Hilden, Germany) with DNAse
I and analyzed by measuring the absorbance at 260 and 280 nm. RNA integrity was confirmed by
RNA electrophoresis on a 1.5% agarose gel containing ethidium bromide.
4.8. Reverse Transcription (RT)
First-strand cDNA was obtained by using the First Strand cDNA Synthesis Kit (GE Healthcare,
Little Chalfont, UK), with random hexamers (GE Healthcare) according to the manufacturer’s protocol.
Reverse Transcription (RT) products were stored at −80 ◦C.
4.9. Real Time PCR
PCRs were performed in a total volume of 25 µL containing Taqman Universal PCRMaster
mix, no AmpErase UNG, and 20 ng of cDNA from each sample; pre-designed, gene-specific
primers and probe sets for each gene (CD3, Hs00174158_m1; CD14, Hs02621496-s1; CD19,
Hs00174333_m1; CD45, Hs00174541_ m1; CD34, HS00156373_m1; RUNX2, Hs00231692_m1; OSTERIX
(SP7) Hs00541729_m1; B2M, Hs999999_m1; COLLAGEN, TYPE I, ALPHA 1 (COL1A1) Hs00164004_m1;
OSTEONECTIN (SPARC) Hs00234160_m1; OSTEOPONTIN (SPP1) Hs00167093_m1; OSTEOCALCIN
(BGLAP) Hs01587813_g1; RANKL (TNFSF11) Hs01092186_m1; PPARG2 Hs01115513_m1; GAPDH,
0802021; Applied Biosystems (Thermo Fisher corporation, Waltham, MA, USA); were obtained from
Assay-on-Demand Gene Expression Products (Applied Biosystems). Real time RT-PCR reactions
were carried out in a two-tube system and in multiplex. The real time amplifications included
10 min at 95 ◦C (AmpliTaq Gold activation), followed by 40 cycles at 95 ◦C for 15 s and at 60 ◦C
for 1 min. Thermocycling and signal detection were performed with an ABI Prism 7300 Sequence
Detector (Applied Biosystems). Signals were detected according to the manufacturer’s instructions.
To evaluate the cell phenotype, mRNA quantification was analyzed by the Relative Standard Curve
Method, as previously described [6]. To compare osteogenic mRNA levels during differentiation in
MSCs before and after ZA treatment, gene expression was calculated after normalization against the
housekeeping genes (B2M, GAPDH) using the relative fold expression differences [34]. Ct values
for each reaction were determined using TaqMan SDS analysis software (7300 System SDS v1.4,
Thermo Fisher corporation, Waltham, MA, USA). For each amount of RNA tested triplicate Ct values
were averaged.
4.10. Statistical Analysis
Paired t-test was used to compare the variation of the same variable at two different time points.
The analysis of covariance (ANCOVA) was used to examine the association of biomarker changes
(at different time points) with BMD. The ANCOVA was repeated for different types of biomarkers
(e.g., CTX, P1NP and ALP) separately. Association between the variations of two different variables at
pairs of time points was estimated through linear.
5. Conclusions
In conclusion, we believe that our work confirms the efficacy of ZA in increasing bone mass in
osteoporotic patients. This effect is not only associated with a decrease of bone turnover, but also with
a stimulation of the osteoblastic lineage leading to a more pronounced gain in bone density compared
to other BPs.
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